Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with temozolomide in treating patients with malignant glioma.
Key facts
- Study ID
- NCT00354068
- Run by
- Duke University
- People needed
- 65
- Starts
- 2004-07-01
- Expected to finish
- 2008-11-01
- Last updated by the study team
- 2013-03-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke Cancer Institute — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.